RenovoRx (NASDAQ:RNXT - Get Free Report) had its price objective upped by Ascendiant Capital Markets from $11.00 to $11.50 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock.
Separately, HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of RenovoRx in a research note on Monday, May 19th.
Get Our Latest Research Report on RenovoRx
RenovoRx Stock Up 0.7%
Shares of RNXT stock traded up $0.01 during mid-day trading on Thursday, hitting $1.40. 196,769 shares of the stock were exchanged, compared to its average volume of 94,522. The firm has a fifty day moving average of $1.05 and a 200 day moving average of $1.15. RenovoRx has a 52-week low of $0.75 and a 52-week high of $1.69. The company has a market cap of $51.20 million, a PE ratio of -2.46 and a beta of 1.32.
RenovoRx (NASDAQ:RNXT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.23 million. Equities analysts predict that RenovoRx will post -0.4 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC purchased a new position in RenovoRx in the 4th quarter valued at about $84,000. Alyeska Investment Group L.P. purchased a new position in RenovoRx in the 1st quarter valued at about $682,000. HighTower Advisors LLC purchased a new position in RenovoRx in the 1st quarter valued at about $40,000. AWM Investment Company Inc. purchased a new position in RenovoRx in the 1st quarter valued at about $2,262,000. Finally, ADAR1 Capital Management LLC lifted its stake in RenovoRx by 143.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 479,883 shares of the company's stock valued at $475,000 after buying an additional 282,633 shares in the last quarter. 3.10% of the stock is owned by hedge funds and other institutional investors.
RenovoRx Company Profile
(
Get Free Report)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Read More
Before you consider RenovoRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RenovoRx wasn't on the list.
While RenovoRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.